The Liraglutide Effects in Atrial Fibrillation (LEAF) Study
JACC: Clinical Electrophysiology · 2026
DOI: 10.1016/j.jacep.2026.03.026 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JACC: Clinical Electrophysiology, 2026. Verfasst von Jeffrey J Goldberger und 13 weiteren Autor:innen. Beteiligte Einrichtung: Cardiovascular Division, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA. Electronic address: j-goldberger…. Hauptthemen laut MEDLINE: Atrial Fibrillation, Catheter Ablation, Epicardial Adipose Tissue, Liraglutide. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NHLBI.
Abstract (Originalsprache)
BACKGROUND: Atrial fibrillation (AF) ablation continues to offer mediocre outcomes, particularly for persistent AF. Obesity and epicardial adipose tissue (EAT) are associated with AF and ablation outcomes. Risk factor modification (RFM), including weight loss, improves AF treatment outcomes. Liraglutide, a glucagon-like peptide-1 receptor agonist, leads to weight loss and EAT reduction. OBJECTIVES: This study sought to test the effects of adjunctive therapy with liraglutide in patients with AF undergoing ablation. METHODS: In this randomized study of overweight/obese (body mass index ≥27 kg/m2) patients with AF (80% persistent AF) who opted for catheter ablation for treatment, 28 patients were assigned to RFM and 31 to risk factor modification (plus liraglutide (RFM+L) for 3 months preablation. EAT was evaluated with serial computed tomography scans at enrollment and preablation, and serial echocardiograms up to 1-year postablation. The primary endpoint was change in left atrial epicardial adipose tissue (LAEAT) volume. Total EAT and recurrent AF at 1 year were secondary endpoints. RESULTS: There were 28 patients (age 61.8 ± 10.3 years, 8 female) assigned to RFM and 31 patients (age 62.2 ± 8.6 years, 8 female) to RFM+L for 3 months preablation. Baseline characteristics were well-balanced between groups with median body mass index of 34.2-37.2 kg/m2. Forty-seven (80%) had persistent AF. One patient in the RFM group and 3 in the RFM+L group opted not to proceed with ablation, and "preablation" testing was performed at the time of this decision. Overall, there were reductions in LAEAT (median -1.0 [Q1-Q3: -4.5 to 1.4] mL; P = 0.02) and weight (-2.8 ± 4.0 kg; P < 0.001) but no difference between groups. One-year freedom from AF/atrial flutter was 81% (95% CI: 62%-91%) for RFM+L and 54% (95% CI: 34%-70%) for RFM (log-rank P = 0.007). Logistic regression models showed RFM+L was associated with lower risk of 12-month recurrence (LAEAT model: OR: 0.19; 95% CI: 0.05-0.73; P = 0.015; EAT model: OR: 0.08; 95% CI: 0.01-0.40; P = 0.002). Change in EAT density was associated with lower recurrence (OR: 0.55; 95% CI: 0.36-0.84; P = 0.006). CONCLUSIONS: Whereas adding liraglutide to RFM in obese patients with AF did not produce significant differences in early weight loss or LAEAT reduction, improved freedom from AF/atrial flutter was noted. Pleiotropic glucagon-like peptide-1 receptor agonist effects may provide novel pharmacologic targets for AF treatment that can substantially improve AF ablation outcomes. (Liraglutide Effect in Atrial Fibrillation [LEAF]; NCT03856632).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiovascular Division, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA. Electronic address: j-goldberger@miami.edu.
- Cardiovascular Division, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.
- Department of Radiology, University of Miami Miller School of Medicine, Miami, Florida, USA.
- Behavioral Medicine Research Center, Department of Psychology, University of Miami Miller School of Medicine, Miami, Florida, USA.
- Division of Biostatistics, Biostatistics Collaboration and Consulting Core, Department of Public Health Sciences, University of Miami, Miami, Florida, USA.
- Biomedical Imaging Research Institute, Cedars Sinai Medical Center, Los Angeles, California, USA.
Förderung
- NHLBI NIH HHS
- NHLBI
Zitieren
APA
Goldberger, J. J., Mitrani, R. D., Fishman, J., Zaatari, G., Lowery, M., Baez-Garcia, C., Aguilar, V., Blandon, C., Hurwitz, B. E., Velasquez, A. H., Lambrakos, L. K., Dey, D., Zarnegarnia, Y., & Iacobellis, G. (2026). The Liraglutide Effects in Atrial Fibrillation (LEAF) Study. JACC: Clinical Electrophysiology. https://doi.org/10.1016/j.jacep.2026.03.026
Vancouver
Goldberger JJ, Mitrani RD, Fishman J, Zaatari G, Lowery M, Baez-Garcia C, et al. The Liraglutide Effects in Atrial Fibrillation (LEAF) Study. JACC: Clinical Electrophysiology. 2026. doi:10.1016/j.jacep.2026.03.026
BibTeX
@article{Goldberger2026,
author = {Goldberger, Jeffrey J and Mitrani, Raul D and Fishman, Joel and Zaatari, Ghaith and Lowery, Maureen and Baez-Garcia, Carmen and Aguilar, Valeria and Blandon, Catherine and Hurwitz, Barry E and Velasquez, Alex H and Lambrakos, Litsa K and Dey, Damini and Zarnegarnia, Yalda and Iacobellis, Gianluca},
title = {The Liraglutide Effects in Atrial Fibrillation (LEAF) Study},
journal = {JACC: Clinical Electrophysiology},
year = {2026},
doi = {10.1016/j.jacep.2026.03.026}
}
EUVIMED